85.05
-2.30 (-2.63%)
| Previous Close | 87.35 |
| Open | 87.35 |
| Volume | 384,223 |
| Avg. Volume (3M) | 736,250 |
| Market Cap | 6,943,685,632 |
| Price / Sales | 185.61 |
| Price / Book | 4.45 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2026 |
| Operating Margin (TTM) | -336.77% |
| Diluted EPS (TTM) | -3.11 |
| Quarterly Revenue Growth (YOY) | 114.80% |
| Total Debt/Equity (MRQ) | 10.98% |
| Current Ratio (MRQ) | 8.49 |
| Operating Cash Flow (TTM) | -234.06 M |
| Levered Free Cash Flow (TTM) | -136.32 M |
| Return on Assets (TTM) | -19.47% |
| Return on Equity (TTM) | -32.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Kymera Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -3.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.80 |
|
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients’ lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.50% |
| % Held by Institutions | 104.98% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 140.00 (Piper Sandler, 64.61%) | Buy |
| Median | 128.00 (50.50%) | |
| Low | 100.00 (Stephens & Co., 17.58%) | Buy |
| Average | 124.40 (46.27%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 91.32 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 03 Mar 2026 | 128.00 (50.50%) | Buy | 86.35 |
| Citigroup | 02 Mar 2026 | 120.00 (41.09%) | Buy | 90.10 |
| Stephens & Co. | 02 Mar 2026 | 100.00 (17.58%) | Buy | 90.10 |
| BTIG | 26 Feb 2026 | 134.00 (57.55%) | Buy | 95.03 |
| 03 Feb 2026 | 138.00 (62.26%) | Buy | 77.22 | |
| Piper Sandler | 26 Feb 2026 | 140.00 (64.61%) | Buy | 95.03 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BOOTH BRUCE | - | 89.00 | -5,335 | -474,815 |
| CHADWICK JEREMY G | - | 89.00 | -1,300 | -115,700 |
| Aggregate Net Quantity | -6,635 | |||
| Aggregate Net Value ($) | -590,515 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 89.00 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BOOTH BRUCE | Director | 15 Apr 2026 | Automatic sell (-) | 2,200 | 89.00 | 195,800 |
| BOOTH BRUCE | Director | 15 Apr 2026 | Automatic sell (-) | 3,135 | 89.00 | 279,015 |
| BOOTH BRUCE | Director | 15 Apr 2026 | Option execute | 2,200 | - | - |
| CHADWICK JEREMY G | Officer | 15 Apr 2026 | Automatic sell (-) | 1,300 | 89.00 | 115,700 |
| CHADWICK JEREMY G | Officer | 15 Apr 2026 | Option execute | 1,300 | - | - |
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Kymera Therapeutics to Participate in Upcoming February Investor Conferences |
| 29 Jan 2026 | Announcement | Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |